Board of Directors and Governance
Steven M. Paul, M.D., Chairman
Dr. Paul is a member of various professional and honorary societies, including Phi Eta Sigma; Alpha Epsilon Delta; Sigma Xi; Phi Beta Kappa; and the Alpha Omega Alpha Honorary Medical Society. He is the recipient of many honors and scientific recognitions, including: The Distinguished Service Medal of the USPHS and the Chief Scientific Officer of the Year Award. In 1997, Dr. Paul was elected to membership in the National Academy of Medicine of the National Academy of Sciences and in 2004 Dr. Paul was elected a Fellow of the American Association for the Advancement of Science (AAAS).
Dr. Paul has authored or co-authored over 500 papers and invited book chapters and was listed as one of the most highly cited scientists in the world (top 50 in Neuroscience) (1980-2000) by the Institute for Scientific Information (I.S.I.), Philadelphia, Pennsylvania. He holds 9 patents on inventions made both at NIH and Lilly. His current work has focused on the role of apoE in the pathogenesis of Alzheimer’s disease. He is also an co-inventor of solanezumab, a humanized anti-Aβ monoclonal antibody currently in late-stage clinical testing by Lilly as a potential disease-modifying treatment for Alzheimer’s disease. Dr. Paul is on the boards of several publicly traded and private biopharmaceutical companies including Alnylam Pharmaceuticals, SAGE Therapeutics and the Sigma Aldrich Company and is also a founder of Sage Therapeutics, Voyager Therapeutics, and Tal Medical, dedicated to discovering and developing novel therapeutics for neurological and psychiatric disorders.
Maria C. Freire, Ph.D.
Dr. Freire obtained her BS degree at the Universidad Peruana Cayetano Heredia in Lima, Peru, and her PhD in Biophysics from the University of Virginia. She completed postgraduate work in Immunology and Virology at the University of Virginia and the University of Tennessee, respectively, and at the John F. Kennedy School of Government, Harvard University. She is widely recognized as an expert in technology commercialization and has a wide range of experience in the public and private biomedical sectors.
Dr. Freire is active on national and international boards and committees. She is the Chair of the Business Advisory Board of the Institute for Research in Biomedicine in Barcelona, Spain; is a Director of Alexandria Real Estate Equities, Inc.; is on the Board of Directors for Exelixis,Inc.; has served as a member of the Commission on a Global Health Risk Framework for the Future of the National Academy of Medicine and the Executive Committee of the United Nations’ Sustainable Development Solutions Network; and was a member of the UN Secretary General’s High-Level Panel on Access to Medicines. She is a member of the National Academy of Medicine and the Council on Foreign Relations.
Dr. Freire is the recipient of numerous awards, including the 2019 “Executive of the Year” Award from NonProfit PRO, the 2017 Gold Stevie Award for “Woman of the Year”, the 2017 Washington Business Journal’s Women Who Mean Business Award, the HHS Secretary’s Award for Distinguished Service, the Arthur S. Flemming Award and the Bayh-Dole Award.
For more information, please visit Dr. Freire's Wikipedia page.
Watch Dr. Freire speak about the transformative nature of biomedical research on The Open Mind.
Email address: email@example.com
Phone: (301) 443-1811
Solomon H. Snyder, M.D., Vice Chairman
Solomon H. Snyder Department of Neuroscience at Johns Hopkins University
Steven C. Mayer, Treasurer
Mrs. William McCormick Blair, Jr. Secretary
Since 1982, Mrs. Blair has had a deep involvement in the Harvard School of Public Health, with a focus on Basic AIDS research. She is Co-Chairman of the Harvard AIDS Initiative International Advisory Council and also serves as an Advisor to the Department of Immunology and Infectious Disease. Through her time living in Asia and Europe as the wife of Ambassador William McCormick Blair, Jr., Mrs. Blair developed an abiding interest in global approach to prevention of infectious diseases and the development of vaccines. She worked as a longtime advisor to Sandoz/Novartis in developing academic collaborations and biotech alliances. She was a consultant to Health Care Ventures for a number of biotech companies.
Kathy Bloomgarden, Ph.D.
Dr. Bloomgarden is a board member of the FNIH and the Partnership for New York City, and a member of the Council on Foreign Relations and the Advisory Board of the Columbia University School of International and Public Affairs. She is the author of Trust: The Secret Weapon of Effective Business Leaders. She holds a BA from Brown University, and an MA and Ph.D. from Columbia University in Political Science. She is fluent in French, and has a working knowledge of Chinese, Italian, and basic German and Russian.
Marijn Dekkers, Ph.D.
From 2010-2016, Dr. Dekkers served as Bayer AG’s CEO. He was the first Bayer CEO to be appointed from outside the company. During his tenure, Bayer acquired the consumer care business of Merck & Co., Inc., floated the material science subgroup on the stock market under the name “Covestro,” and systematically focused on the life sciences businesses. Under Dr. Dekkers’ leadership, Bayer’s previous structure - comprising a strategic management holding company and operational subgroups - was replaced by an integrated organization under the umbrella of the Bayer brand. While there he served for two years as President of the German Chemical Industry Association (VCI), Frankfurt.
From 2002-2009, Dr. Dekkers served as CEO of Thermo Fisher Scientific (he was COO from 2000-2002). As CEO of Thermo, he initiated extensive restructuring measures, divesting various organizational units and strengthening the company’s core business by means of targeted acquisitions, including the purchase in 2006 of the significantly larger laboratory consumables supplier Fisher Scientific. This created a global life sciences company which now employs 55,000 people and generates annual sales of $18 billion.
Dr. Dekkers began his career in 1985 as a research scientist at General Electric, gaining experience in various units of the company before joining Honeywell International in 1995.
Dr. Dekkers received his Ph.D. and M.S. in Chemical Engineering from the University of Eindhoven and his B.S. in chemistry from the Radboud University, both in The Netherlands. He holds dual U.S. and Dutch citizenships.
James H. Donovan
Paul L. Herrling, Ph.D.
“Paul’s expertise with tropical infectious diseases will be vital to us as we continue our relationship with the Bill and Melinda Gates Foundation and on other global health initiatives,” according to Charles A. Sanders, MD, FNIH chairman. “Bettering global health is a priority for the FNIH.”
Prior to his current position, Herrling was head of both Novartis Institutes for Developing World Medical Research supervising four institutes. In addition to the FNIH, he serves on boards of The Scripps Research Institute, University Council of the University of Basel, Scientific Advisory Committee of the Drugs for Neglected Diseases Initiative, and is Vice President of the Board of Swiss Federal Institutes of Technology.
“Paul’s strong global network and deep understanding of neglected diseases will make him an invaluable board member,” according to Kathy Bloomgarden, FNIH board member. “He’s dedicated himself to advance biomedical research and provided innovative thinking to the access to medicines debate. He will be an asset in helping to overcome some of the most challenging and integral health issues of today.”
Thomas R. Insel, M.D.
Prior to his appointment at the NIMH, Dr. Insel was a Professor in the Department of Psychiatry and Director of the Center for Behavioral Neuroscience at Emory University School of Medicine. He also served as Director of the Center for Autism Research and is a member of the scientific advisory board at the Autism Science Foundation. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe
Judy Lansing Kovler, Ph.D.
Ronald L. Krall, M.D.
Former Chief Medical Officer for GlaxoSmithKline (Retired), Dr. Krall worked for four companies (Lorex Pharmaceuticals, Abbott Laboratories, Zeneca/AstraZeneca and GlaxoSmithKline) over 25 years. His areas of expertise include the ethics of human subject experimentation, drug development, regulatory science and the safety of medicines. Dr. Krall was a founding member of the Observational Medical Outcomes Partnership, served on its Executive Committee and led its research subcommittee.
Dr. Krall is a graduate of Phillips Exeter Academy, holds a B.A. in mathematics from Swarthmore College, an M.D. from the University of Pittsburgh, was a Staff Associate in the Epilepsy Branch of the National Institutes of Health, and completed his training in neurology and a fellowship in Clinical Pharmacology at the University of Rochester.
Dr. Krall currently makes his home in Steamboat Springs, Colorado, where he serves as Chair of the Board of the Yampa Valley Community Foundation, is President of the Timbers Water and Sanitation District, and serves as advisor and ranch manager for BookTrails, a 501(c)3 literacy organization for children. Dr. Krall and his wife own and operate Off the Beaten Path, an independent bookstore, coffeehouse and bakery café (www.steamboatbooks.com) - one of the 28 “coolest” independent bookstores in America (https://matadornetwork.com/read/28-coolest-independent-book-stores-us/).
Freda C. Lewis-Hall, M.D., DFAPA, MFPM
Before joining Pfizer, Dr. Lewis-Hall held senior leadership positions of Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals; Senior Vice President, US Pharmaceuticals at Bristol Myers Squibb; Vice President, Research and Development, Product Development at Pharmacia Corporation; and Product Team Leader and Director at Eli Lilly and Company.
Dr. Lewis-Hall currently serves on the Board of Fellows of The Harvard Medical School, the Board of Advisors of the Dell Medical School and the Board of Governors for the Patient-Centered Outcomes Research Institute. She currently serves on the corporate boards of Milliken and Company, a global diversified industrial manufacturer; 1Life Healthcare, Inc., a health services company; Exact Sciences, Inc., a molecular diagnostics company; and SpringWorks Therapeutics, a biopharmaceutical company.
Prior to joining the biopharmaceutical industry, Dr. Lewis-Hall served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. She earned a B.A. in Natural Sciences from The Johns Hopkins University and an M.D. from Howard University College of Medicine. She launched her medical career as a practicing physician and then focused her academic research on the effects of health care disparities and the impact of mental illness on families and communities.
Dr. Lewis-Hall is a Distinguished Fellow of the American Psychiatric Association and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. She is a frequent speaker on issues such as improving patient safety and health outcomes, reducing stigma and health care disparities, women’s health, public health, corporate leadership and diversity. Dr. Lewis-Hall is an accomplished developer of consumer education and medical outreach programs, including national television and radio shows such as segments on Dr. Phil, The Doctors, THE REAL, TEDMed, The Urban Health Report and multiple online sites.
Julie Bell Lindsay
Prior to her time at CAQ, Ms. Lindsay served as was Managing Director & Deputy Head of Global Regulatory Affairs at Citigroup Inc. and as Counsel for Hogan Lovells.
In addition, among other endeavors, she served as Counsel to Commissioner Cynthia Glassman at the U.S. Securities and Exchange Commission. Ms. Lindsay holds a B.A. in political science from The Ohio State University as well as a J.D. from Vanderbilt Law School.
Edison T. Liu, M.D., Ph.D.
Joel S. Marcus
Mr. Marcus has built Alexandria’s unique business model around four business verticals — real estate, venture investments, thought leadership, and corporate responsibility. With its core focus on real estate, Alexandria has a proven track record of developing Class A buildings on urban life science and technology campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus founded the company’s venture capital arm, Alexandria Venture Investments, to provide strategic investment capital to innovative life science and technology entities developing breakthrough therapies and technologies. Mr. Marcus introduced the company’s thought leadership platform in 2011, when he co-founded the renowned Alexandria Summit®. The Alexandria Summit convenes a diverse group of visionary partners and key stakeholders — from the pharmaceutical, biotechnology, agribusiness, technology, medical, academic, venture capital, private equity, philanthropic, patient advocacy, and government communities — to address the most critical challenges in global healthcare, agriculture, and the environment. Focusing on sustainability and philanthropy, Alexandria’s corporate responsibility business vertical affirms the company’s commitment to making a positive impact on the world. Mr. Marcus is also personally engaged in numerous mission-critical philanthropic efforts, including through his service as Chair of the Navy SEAL Foundation’s 2017 New York City Benefit, which raised $12.8 million to help support the Naval Special Warfare community and their families.
Mr. Marcus was one of the original architects and co-founders of Accelerator Life Science Partners, for which he serves on the board of directors, and AgTech Accelerator Corporation, for which he serves as Chairman of the board. He also serves on the boards of Applied Therapeutics Inc., Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Boragen Inc., Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MeiraGTx Limited, and Yumanity Therapeutics; Biotechnology Innovation Organization (BIO), the Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, MassBio, NewYorkBIO, and The Scripps Research Institute; the 9/11 Memorial & Museum, the Navy SEAL Foundation, the Partnership for New York City, and Robin Hood Foundation; as well as on Nareit’s 2018 Executive Board.
Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. During that time, he acquired an expertise in the biopharmaceutical industry and was one of the principal architects of the Kirin-Amgen EPO joint venture in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs.
He was named one of Real Estate Forum’s 2017 Best Bosses in commercial real estate and was previously a recipient of the EY Entrepreneur Of The Year Award (Los Angeles — Real Estate). Mr. Marcus earned his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.
Gilbert S. Omenn, M.D., Ph.D.
He was a Research Associate with Christian B. Anfinsen at the National Institute of Arthritic and Metabolic Diseases; a Howard Hughes Medical Institute Investigator at the University of Washington (UW); and a member of the National Cancer Advisory Board; the National Heart, Lung and Blood Institute Council, the Society of Fellows of the National Center for Minority Health & Health Disparities and the Scientific Management Review Committee for the National Institutes of Health. He was Dean of the School of Public Health & Community Medicine at the UW and Executive Vice-President for Medical Affairs and CEO of the Health System at the University of Michigan. He served as a White House Fellow at the U.S. Atomic Energy Commission, Associate Director of the White House Office of Science & Technology Policy and the Office of Management & Budget, and President of the American Association for the Advancement of Science. He chaired the Presidential/Congressional Commission on Risk Assessment & Risk Management in the 1990s. He served on the boards of Amgen, Inc. and Rohm & Haas Company. He currently serves on boards of the Hastings Center for Bioethics, the Center for Public Integrity, the Weizmann Institute of Science and biotech firms.
Dr. Omenn is an elected member of the National Academy of Medicine, the Association of American Physicians and the American Academy of Arts and Sciences and a fellow of the American College of Physicians, the National Academy for Social Insurance and the AAAS. He received the Walsh McDermott Medal from the National Academy of Medicine and the David E. Rogers Award from the Association of American Medical Colleges. He holds a B.A. from Princeton, an M.D. from Harvard, and a Ph.D. in genetics from the University of Washington. He has three children and seven grandchildren. He is a musician and tennis player.
Jillian Sackler, D.B.E
Mrs. Safra holds honorary doctorates from institutions including the Hebrew University of Jerusalem, Tel Aviv University, Brandeis University, and Imperial College London. She is an honorary fellow of King's College London and of the Courtauld Institute of Art. In addition, she is a Commandeur of France's Ordre des Arts et des Lettres and Officier de la Légion d'honneur.
Mrs. Safra and the Edmond J. Safra Foundation were the lead benefactors in the construction of the Edmond J. Safra Family Lodge, a guest house on the campus of the National Institutes of Health for patients being treated at the NIH Clinical Center and their families.
Charles A. Sanders, M.D.
Ellen V. Sigal, Ph.D.
In her over twenty years of commitment to advancing the war on cancer, Dr. Sigal has served in a number of critical public positions. Dr. Sigal was a Presidential Appointee to the National Cancer Advisory Board from 1992-1998 where she chaired the Budget and Planning Committee that oversees the federal cancer budget. Additionally, Dr. Sigal also serves on the National Dialogue on Cancer's research advisory panel and previously held leadership positions with the Foundation for the American Society of Clinical Oncology.
In 1998, Dr. Sigal was named Vice Chairman of the Board of The March - a national grassroots advocacy group that brought thousands of volunteers to Washington to liaise with Congress and to set a new advocacy agenda for cancer research and treatment. Dr. Sigal also has been instrumental in harnessing the energies of Hollywood on behalf of cancer research - serving as President of The Creative Community Task Force for Cancer Research.
Prior to her work in cancer research advocacy, Dr. Sigal enjoyed a highly successful and influential business career in commercial real estate. Her firm, Sigal Development, financed and developed major projects throughout the Washington and mid-Atlantic region - a portfolio in excess of one billion dollars. For her efforts on behalf of cancer research advocacy, Dr. Sigal received the 1998 American Association for Cancer Research National Leadership Award, the 1999 Sidney Kimmel Cancer Center National Leadership Award, and the 2002 American Society of Clinical Oncology Special Recognition Award.
Dr. Sigal received her Ph.D. from Rutgers University in Russian History.
Russell W. Steenberg
Paul Stoffels, M.D.
Elias Zerhouni, M.D.
Dr. Zerhouni was most recently the President, Global Research & Development, and a member of the Executive Committee for Sanofi from January 2011 to July 2018
Dr. Zerhouni’s academic career was spent at the Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical engineering and senior adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health from 2002 to 2008.
In 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys.
Dr. Zerhouni also served as senior fellow to the Bill and Melinda Gates foundation from 2009 to 2010. He authored more than 200 scientific publications and is a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering.
Ex Officio Directors
Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health
Paul Berg, Ph.D. Cahill Professor in Biochemistry (Emeritus), Stanford University School of Medicine
Sherry Lansing Founder and Chief Executive Officer, The Sherry Lansing Foundation
Paul M. Montrone, Ph.D. Chairman, Perspecta Trust
The Honorable John Edward Porter Hogan Lovells US, LLP
Ann Lurie President, Lurie Holdings; President and Treasurer, Ann and Robert H. Lurie Foundation
Samuel O. Thier, M.D. Professor of Medicine and Health Care Policy, Emeritus, Harvard Medical School; Massachusetts General Hospital
Patrick C. Walsh, M.D. University Distinguished Service Professor, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions